Cheaper cancer drug on the horizon? new biosimilar QL2109 tested in healthy men
NCT ID NCT07400744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial tests QL2109, a biosimilar to the multiple myeloma drug Darzalex, in 102 healthy Chinese men. The goal is to see if the body processes QL2109 similarly to Darzalex and to check for side effects. It does not test the drug's ability to treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL2109 (a biosimilar to daratumumab)
What this could lead to
If QL2109 works like Darzalex, it could offer a more affordable treatment option for multiple myeloma.
What could go wrong
This is an early Phase 1 study in healthy people, not patients. It only checks drug levels and safety, not whether it fights cancer. Success is far from certain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••